{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:57:57Z","timestamp":1790697477496,"version":"4.1.0"},"reference-count":66,"publisher":"IMR Press","issue":"9","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Heart failure with preserved ejection fraction (HFpEF) represents a heterogeneous clinical syndrome characterized by complex pathophysiological mechanisms and substantial diagnostic and prognostic challenges. Recently, circulating biomarkers have emerged as potential tools for improving risk stratification and disease characterization in this population. Among these biomarkers, soluble suppression of tumorigenicity-2 (sST2) and galectin-3 (Gal-3) have gained particular attention due to their association with myocardial fibrosis, inflammation, and adverse cardiac remodeling. This scoping review aimed to evaluate the current evidence on the diagnostic and prognostic roles of sST2 and Gal-3 in patients with HFpEF. A literature search was conducted in PubMed and ScienceDirect to identify studies investigating the clinical significance of these biomarkers in HFpEF. Titles and abstracts were screened, and eligible studies were assessed through full-text review according to predefined inclusion criteria. Ultimately, 11 studies were included in the qualitative synthesis. Evidence from the available literature suggests that both sST2 and Gal-3 are associated with markers of myocardial fibrosis, inflammation, and disease severity in HFpEF. Elevated circulating levels of these biomarkers have been linked to poorer clinical outcomes, including an increased risk of hospitalization and mortality. However, variability across studies in study populations, biomarker thresholds, and methodological approaches limits the direct translation of these findings into routine clinical practice. Overall, sST2 and Gal-3 appear to hold promise as complementary biomarkers for risk stratification in HFpEF. Nonetheless, further large-scale prospective studies are needed to clarify the clinical utility of these biomarkers and determine the subsequent integration into multimarker strategies for the management of patients with HFpEF.<\/jats:p>","DOI":"10.31083\/rcm51830","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:57:11Z","timestamp":1790693831000},"source":"Crossref","is-referenced-by-count":0,"title":["The Role of Soluble Suppression of Tumorigenicity-2 and Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Scoping Review of the Literature"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5453-792X","authenticated-orcid":true,"given":"Konstantina","family":"Ntalekou","sequence":"first","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 11527 Athens, Greece"},{"name":"Cardiology Department, \u201cTzaneio\u201d General Hospital of Piraeus, 18536 Piraeus, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5768-9125","authenticated-orcid":true,"given":"Panagiotis","family":"Iliakis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 11527 Athens, Greece"},{"name":"Division of Cardiology, Angiology and Internal Emergency Medicine, Department of Medicine, Knappschaft Kliniken University Hospital Bochum, Ruhr University Bochum, 44892 Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4592-3077","authenticated-orcid":true,"given":"Nikitas","family":"Katsillis","sequence":"additional","affiliation":[{"name":"Cardiology Department, \u201cTzaneio\u201d General Hospital of Piraeus, 18536 Piraeus, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5198-6314","authenticated-orcid":true,"given":"Nikolaos","family":"Patsourakos","sequence":"additional","affiliation":[{"name":"Cardiology Department, \u201cTzaneio\u201d General Hospital of Piraeus, 18536 Piraeus, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-9712","authenticated-orcid":true,"given":"Dimitrios","family":"Tsiachris","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-3447","authenticated-orcid":true,"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7747-4445","authenticated-orcid":true,"given":"Polykarpos Christos","family":"Patsalis","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Angiology and Internal Emergency Medicine, Department of Medicine, Knappschaft Kliniken University Hospital Bochum, Ruhr University Bochum, 44892 Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6340-3996","authenticated-orcid":true,"given":"Christina","family":"Chrysohoou","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-6725","authenticated-orcid":true,"given":"Konstantinos","family":"Tsioufis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Savji N, Meijers WC, Bartz TM, Bhambhani V, Cushman M, Nayor M, et al. The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. JACC. Heart Failure. 2018; 6: 701\u2013709.","DOI":"10.1016\/j.jchf.2018.05.018"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021; 42: 3599\u20133726.","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement. Journal of the American College of Cardiology. 2023; 81: 1810\u20131834.","DOI":"10.1016\/j.jacc.2023.01.049"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2023; 44: 3627\u20133639.","DOI":"10.1093\/eurheartj\/ehad195"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145: e895\u2013e1032.","DOI":"10.1161\/CIR.0000000000001063"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Pieske B, Tsch\u00f6pe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure. 2020; 22: 391\u2013412.","DOI":"10.1002\/ejhf.1741"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Suzuki S, Kaikita K, Yamamoto E, Sueta D, Yamamoto M, Ishii M, et al. H2 FPEF score for predicting future heart failure in stable outpatients with cardiovascular risk factors. ESC Heart Failure. 2020; 7: 65\u201374.","DOI":"10.1002\/ehf2.12570"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Anker SD, Usman MS, Anker MS, Butler J, B\u00f6hm M, Abraham WT, et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. European Journal of Heart Failure. 2023; 25: 936\u2013955.","DOI":"10.1002\/ejhf.2894"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Hanna EB. Practical Cardiovascular Medicine. Wiley: Hoboken, NJ. 2022.","DOI":"10.1002\/9781119832737"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Nair N. Epidemiology and pathogenesis of heart failure with preserved ejection fraction. Reviews in Cardiovascular Medicine. 2020; 21: 531\u2013540.","DOI":"10.31083\/j.rcm.2020.04.154"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Chrysohoou C, Konstantinou K, Tsioufis K. The Role of NT-proBNP Levels in the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction-It Is Not Always a Hide-and-Seek Game. Journal of Cardiovascular Development and Disease. 2024; 11: 225.","DOI":"10.3390\/jcdd11070225"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Sorimachi H, Omote K, Borlaug BA. Clinical Phenogroups in Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics. 2021; 17: 483\u2013498.","DOI":"10.1016\/j.hfc.2021.02.009"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Campbell P, Rutten FH, Lee MM, Hawkins NM, Petrie MC. Heart failure with preserved ejection fraction: everything the clinician needs to know. Lancet (London, England). 2024; 403: 1083\u20131092.","DOI":"10.1016\/S0140-6736(23)02756-3"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology. 2013; 62: 263\u2013271.","DOI":"10.1016\/j.jacc.2013.02.092"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Failure Reviews. 2022; 27: 625\u2013643.","DOI":"10.1007\/s10741-021-10105-w"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Kayani M, Fatima N, Yarra PC, Almansouri NE, K D, Balasubramanian A, et al. Novel Biomarkers in Early Detection of Heart Failure: A Narrative Review. Cureus. 2024; 16: e53445.","DOI":"10.7759\/cureus.53445"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Carlsen CM, Bay M, Kirk V, G\u00f8tze JP, K\u00f8ber L, Nielsen OW. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study. European Journal of Heart Failure. 2012; 14: 240\u2013247.","DOI":"10.1093\/eurjhf\/hfs003"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Pan W, Yang D, Yu P, Yu H. Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions. BMC Cardiovascular Disorders. 2020; 20: 208.","DOI":"10.1186\/s12872-020-01493-2"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Yin QS, Shi B, Dong L, Bi L. Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure. Journal of Geriatric Cardiology: JGC. 2014; 11: 79\u201382.","DOI":"10.3969\/j.issn.1671-5411.2014.01.014"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Annals of Internal Medicine. 2018; 169: 467\u2013473.","DOI":"10.7326\/M18-0850"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Huang A, Qi X, Hou W, Qi Y, Zhao N, Liu K. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction. Acta Cardiologica. 2018; 73: 41\u201348.","DOI":"10.1080\/00015385.2017.1325617"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Cui Y, Qi X, Huang A, Li J, Hou W, Liu K. Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2018; 24: 5139\u20135146.","DOI":"10.12659\/MSM.908840"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Song Y, Li F, Xu Y, Liu Y, Wang Y, Han X, et al. Prognostic value of sST2 in patients with heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology. 2020; 304: 95\u2013100.","DOI":"10.1016\/j.ijcard.2020.01.039"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Jirak P, Pistulli R, Lichtenauer M, Wernly B, Paar V, Motloch LJ, et al. Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls. Journal of Clinical Medicine. 2020; 9: 1130.","DOI":"10.3390\/jcm9041130"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Jiang J, Yang B, Sun Y, Jin J, Zhao Z, Chen S. Diagnostic Value of Serum Concentration of Galectin-3 in Patients With Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine. 2022; 8: 829151.","DOI":"10.3389\/fcvm.2021.829151"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Sugano A, Seo Y, Ishizu T, Sai S, Yamamoto M, Hamada-Harimura Y, et al. Soluble ST2 and brain natriuretic peptide predict different mode of death in patients with heart failure and preserved ejection fraction. Journal of Cardiology. 2019; 73: 326\u2013332.","DOI":"10.1016\/j.jjcc.2018.10.012"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Emdin M, Aimo A, Vergaro G, Bayes-Genis A, Lup\u00f3n J, Latini R, et al. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. Journal of the American College of Cardiology. 2018; 72: 2309\u20132320.","DOI":"10.1016\/j.jacc.2018.08.2165"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Kanukurti J, Mohammed N, Sreedevi NN, Khan SA, Baba KSSS, Bhaskar MV, et al. Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction. Journal of Laboratory Physicians. 2020; 12: 126\u2013132.","DOI":"10.1055\/s-0040-1716608"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Trippel TD, Mende M, D\u00fcngen HD, Hashemi D, Petutschnigg J, Nolte K, et al. The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study. ESC Heart Failure. 2021; 8: 829\u2013841.","DOI":"10.1002\/ehf2.13174"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Chen Y, Guan J, Qi C, Wu Y, Wang J, Zhao X, et al. Association of point-of-care testing for sST2 with clinical outcomes in patients hospitalized with heart failure. ESC Heart Failure. 2024; 11: 2857\u20132868.","DOI":"10.1002\/ehf2.14860"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Gaggin HK, Szymonifka J, Bhardwaj A, Belcher A, De Berardinis B, Motiwala S, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC. Heart Failure. 2014; 2: 65\u201372.","DOI":"10.1016\/j.jchf.2013.10.005"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"De Marco C, Claggett BL, de Denus S, Zile MR, Huynh T, Desai AS, et al. Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial. ESC Heart Failure. 2021; 8: 1130\u20131138.","DOI":"10.1002\/ehf2.13153"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Gravning J, Askevold ET, Nymo SH, Ueland T, Wikstrand J, McMurray JJV, et al. Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial. Circulation. Heart Failure. 2014; 7: 96\u2013103.","DOI":"10.1161\/CIRCHEARTFAILURE.113.000450"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Masson S, Anand I, Favero C, Barlera S, Vago T, Bertocchi F, et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation. 2012; 125: 280\u2013288.","DOI":"10.1161\/CIRCULATIONAHA.111.044149"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Schroten NF, Ruifrok WPT, Kleijn L, Dokter MM, Sillj\u00e9 HH, Lambers Heerspink HJ, et al. Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial). American Heart Journal. 2013; 166: 357\u2013364.e2.","DOI":"10.1016\/j.ahj.2013.05.009"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Sanders-van Wijk S, van Empel V, Davarzani N, Maeder MT, Handschin R, Pfisterer ME, et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. European Journal of Heart Failure. 2015; 17: 1006\u20131014.","DOI":"10.1002\/ejhf.414"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. Journal of the American College of Cardiology. 2011; 58: 1881\u20131889.","DOI":"10.1016\/j.jacc.2011.03.072"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet (London, England). 2022; 400: 1938\u20131952.","DOI":"10.1016\/S0140-6736(22)02076-1"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Meijers WC, Bayes-Genis A, Mebazaa A, Bauersachs J, Cleland JGF, Coats AJS, et al. Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC). European Journal of Heart Failure. 2021; 23: 1610\u20131632.","DOI":"10.1002\/ejhf.2346"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Sakane K, Kanzaki Y, Okuno T, Nakayama S, Hasegawa H, Tokura D, et al. Left Atrial Remodeling Related to Disproportionately Low B-Type Natriuretic Peptide in Acute Heart Failure Patients with Atrial Fibrillation. The American Journal of Cardiology. 2023; 209: 128\u2013137.","DOI":"10.1016\/j.amjcard.2023.09.071"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Januzzi JL Jr, Myhre PL. The Challenges of NT-proBNP Testing in HFpEF: Shooting Arrows in the Wind. JACC. Heart Failure. 2020; 8: 382\u2013385.","DOI":"10.1016\/j.jchf.2020.03.003"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Kang SH, Park JJ, Choi DJ, Yoon CH, Oh IY, Kang SM, et al. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF. Heart (British Cardiac Society). 2015; 101: 1881\u20131888.","DOI":"10.1136\/heartjnl-2015-307782"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Bachmann KN, Gupta DK, Xu M, Brittain E, Farber-Eger E, Arora P, et al. Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure. JACC. Heart Failure. 2021; 9: 192\u2013200.","DOI":"10.1016\/j.jchf.2020.10.008"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Najjar E, Fax\u00e9n UL, Hage C, Donal E, Daubert JC, Linde C, et al. ST2 in heart failure with preserved and reduced ejection fraction. Scandinavian Cardiovascular Journal: SCJ. 2019; 53: 21\u201327.","DOI":"10.1080\/14017431.2019.1583363"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Dudek M, Ka\u0142u\u017cna-Oleksy M, Migaj J, Sawczak F, Krysztofiak H, Lesiak M, et al. sST2 and Heart Failure-Clinical Utility and Prognosis. Journal of Clinical Medicine. 2023; 12: 3136.","DOI":"10.3390\/jcm12093136"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Lotierzo M, Dupuy AM, Kalmanovich E, Roubille F, Cristol JP. sST2 as a value-added biomarker in heart failure. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2020; 501: 120\u2013130.","DOI":"10.1016\/j.cca.2019.10.029"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Morfino P, Aimo A, Castiglione V, Vergaro G, Emdin M, Clerico A. Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond. Journal of Cardiovascular Development and Disease. 2022; 9: 256.","DOI":"10.3390\/jcdd9080256"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Sinning C, Kempf T, Schwarzl M, Lanfermann S, Ojeda F, Schnabel RB, et al. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction. International Journal of Cardiology. 2017; 227: 272\u2013277.","DOI":"10.1016\/j.ijcard.2016.11.110"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Riccardi M, Myhre PL, Zelniker TA, Metra M, Januzzi JL, Inciardi RM. Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide. Journal of Cardiovascular Development and Disease. 2023; 10: 468.","DOI":"10.3390\/jcdd10110468"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Aimo A, Januzzi JL Jr, Bayes-Genis A, Vergaro G, Sciarrone P, Passino C, et al. Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week. Journal of the American College of Cardiology. 2019; 74: 2193\u20132203.","DOI":"10.1016\/j.jacc.2019.08.1039"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Januzzi JL, Mebazaa A, Di Somma S. ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel. The American Journal of Cardiology. 2015; 115: 26B\u201331B.","DOI":"10.1016\/j.amjcard.2015.01.037"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Pacho C, Domingo M, N\u00fa\u00f1ez R, Lup\u00f3n J, N\u00fa\u00f1ez J, Barallat J, et al. Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients. BMC Geriatrics. 2018; 18: 109.","DOI":"10.1186\/s12877-018-0807-2"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Plawecki M, Morena M, Kuster N, Chenine L, Leray-Moragues H, Jover B, et al. sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction. Mediators of Inflammation. 2018; 2018: 3952526.","DOI":"10.1155\/2018\/3952526"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Anand IS, Rector TS, Kuskowski M, Snider J, Cohn JN. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circulation. Heart Failure. 2014; 7: 418\u2013426.","DOI":"10.1161\/CIRCHEARTFAILURE.113.001036"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circulation. Heart Failure. 2011; 4: 180\u2013187.","DOI":"10.1161\/CIRCHEARTFAILURE.110.958223"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Echouffo-Tcheugui JB, Zhang S, Florido R, Pankow JS, Michos ED, Goldberg RB, et al. Galectin-3, Metabolic Risk, and Incident Heart Failure: The ARIC Study. Journal of the American Heart Association. 2024; 13: e031607.","DOI":"10.1161\/JAHA.123.031607"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, et al. The fibrosis marker galectin-3 and outcome in the general population. Journal of Internal Medicine. 2012; 272: 55\u201364.","DOI":"10.1111\/j.1365-2796.2011.02476.x"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Yao L, Tan Y, Chen F. Correlation between galectin-3, RDW, Hepc, HS and ferritin and prognosis of patients with acute onset of chronic heart failure. BMC Cardiovascular Disorders. 2022; 22: 471.","DOI":"10.1186\/s12872-022-02847-8"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Rabkin SW, Tang JKK. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review. Heart Failure Reviews. 2021; 26: 799\u2013812.","DOI":"10.1007\/s10741-020-09913-3"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Baccouche BM, Rhodenhiser E. Galectin-3 and HFpEF: Clarifying an Emerging Relationship. Current Cardiology Reviews. 2023; 19: 19\u201326.","DOI":"10.2174\/1573403X19666230320165821"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal. 2012; 33: 2290\u20132296.","DOI":"10.1093\/eurheartj\/ehs077"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Rehman SU, Martinez-Rumayor A, Mueller T, Januzzi JL Jr. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2008; 392: 41\u201345.","DOI":"10.1016\/j.cca.2008.03.002"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. The American Journal of Cardiology. 2005; 95: 948\u2013954.","DOI":"10.1016\/j.amjcard.2004.12.032"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RRJ, Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. European Journal of Heart Failure. 2010; 12: 826\u2013832.","DOI":"10.1093\/eurjhf\/hfq091"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Pecherina T, Kutikhin A, Kashtalap V, Karetnikova V, Gruzdeva O, Hryachkova O, et al. Serum and Echocardiographic Markers May Synergistically Predict Adverse Cardiac Remodeling after ST-Segment Elevation Myocardial Infarction in Patients with Preserved Ejection Fraction. Diagnostics (Basel, Switzerland). 2020; 10: 301.","DOI":"10.3390\/diagnostics10050301"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Meijers WC, van der Velde AR, Muller Kobold AC, Dijck-Brouwer J, Wu AH, Jaffe A, et al. Variability of biomarkers in patients with chronic heart failure and healthy controls. European Journal of Heart Failure. 2017; 19: 357\u2013365.","DOI":"10.1002\/ejhf.669"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/9\/10.31083\/RCM51830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:57:14Z","timestamp":1790693834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/9\/10.31083\/RCM51830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":66,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2153-8174(26)03754-0"],"URL":"https:\/\/doi.org\/10.31083\/rcm51830","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]},"article-number":"51830"}}